Newsroom | 10259 results

SAN FRANCISCO--(BUSINESS WIRE)--Universal Brain Receives FDA 510(k) Clearance for Rapid Brain-Function Measurement Platform for Psychiatry...

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options, announced today the pricing of an underwritten registered direct offering of 3,776,436 shares of its common stock at a price of $26.48 per share. All of the shares are being offered by Alto. The gross proceeds from the offering are expected...

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced results from a planned interim analysis of the ongoing long-term extension (LTE) study evaluating alixorexton in adults with narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2). Across all dose groups in both NT1 and NT2 participants, alixorexton demonstrated sustained clinically meaningful improvement from baseline1 on the Maintenance of Wakefulness Test (MWT) and Epworth Sleepiness Scale (ESS) at week 24 of the LTE, approxim...

BOSTON--(BUSINESS WIRE)--ZETA SURGICAL today announced that its Zeta TMS Robotic System has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). The device is classified as a Class II stereotaxic instrument under 21 CFR 882.4560 and product codes SGE and QFF (K261471). Transcranial magnetic stimulation, or TMS, is a non-invasive therapy used primarily for treatment-resistant depression, which affects approximately one-third of patients with major depressive disorder. TMS...

سان ماتيو، كاليفورنيا--(BUSINESS WIRE)--أسهمت أول تجربة سريرية عشوائية محكمة (RCT) من نوعها، نُشرت اليوم في مجلة Schizophrenia Bulletin، وأجراها باحثون من جامعة كاليفورنيا في سان فرانسيسكو (UCSF) بتمويل جزئي من المعهد الوطني للصحة النفسية (NIMH)، في إثراء قاعدة الأدلة العلمية المتزايدة التي تشير إلى الفوائد المحتملة للنظام الغذائي الكيتوني في علاج الاضطرابات الذهانية. وأظهرت الدراسة، التي ضمّت مشاركين مصابين باضطرابات طيف الفصام أو اضطراب ثنائي القطب من النوع الأول، أن اتباع النظام الغذائي الكيت...

FRANKLIN, Tenn.--(BUSINESS WIRE)--Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its second quarter 2026 results on Tuesday, July 28, 2026, after the close of the market. Acadia will host a conference call with institutional investors and analysts on Wednesday, July 29, 2026 at 9:00 a.m. ET. A live broadcast of the conference call will be available at www.acadiahealthcare.com in the “Investors” section of the website, and the archived webcast will be availabl...

LA JOLLA, Calif.--(BUSINESS WIRE)--Arialys Announces U.S. FDA Fast Track Designation for ART5803, the First Precision Therapeutic Candidate in Development for the Treatment of ANRE...

SAN FRANCISCO--(BUSINESS WIRE)--Amprion, a global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing, and Modality.AI, a leader in AI-enabled multimodal clinical assessments, today announced a collaboration to explore how molecular biomarkers and objective digital assessments can be combined to improve the characterization of central nervous system (CNS) disorders. The collaboration brings together Amprion's expertise in detecting disease-specific misfo...

美国加利福尼亚州圣马特奥--(BUSINESS WIRE)--(美国商业资讯)-- 今日发表于《Schizophrenia Bulletin》的一项开创性随机对照试验（RCT）进一步为生酮饮食在精神病性障碍治疗中的潜在价值提供了新的研究证据。该研究由 University of California, San Francisco（UCSF）研究人员开展，并获得 National Institute of Mental Health（NIMH）部分资助。研究纳入了精神分裂症谱系障碍或Ⅰ型双相情感障碍患者。结果显示，在为期一个月的随机对照开放标签研究阶段，与维持常规饮食的受试者相比，采用生酮饮食的受试者代谢状况迅速改善。此外，在随后可自愿参加的为期四个月的单组生酮饮食延长期研究中，持续坚持生酮饮食的受试者在代谢、精神症状及认知功能等多项评估指标上均取得了显著改善。 研究共纳入 58 名受试者，其中 47 名完成了为期一个月的随机对照试验，接受生酮饮食干预组与常规饮食对照组的比较。随后，25 名受试者选择继续参加单组延长期研究，使生酮饮食干预总时长延长至四个月。研究结果显示，该干预方案具有较...

加州，聖馬提歐--(BUSINESS WIRE)--(美國商業資訊)-- 《精神分裂症公報》(Schizophrenia Bulletin) 今天發表了一份開創性的隨機對照試驗 (RCT) 報告。越來越多研究探討應用生酮飲食治療精神病性障礙的潛在效益，這項由加州大學舊金山分校 (UCSF) 的研究人員進行、並獲美國國家心理健康研究所 (NIMH) 贊助部分資金的試驗為這類研究報告增添一筆新發現。這項研究徵求患有精神分裂症譜系障礙或I型躁鬱症的受試者進行為期一個月的開放標籤階段初始隨機對照試驗。結果顯示，與一般飲食相比，生酮飲食能迅速改善代謝狀況。此外，某些受試者繼續進行為期四個月的生酮飲食單臂研究，他們的代謝、精神狀況及認知功能指標均呈現顯著改善。 在錄取的58名受試者中，47人完成了為期一個月的初步生酮飲食與一般飲食效果對照研究。其中25名受試者選擇繼續攝取生酮飲食，將試驗總時長延長至四個月（即單臂延長研究）。研究結果顯示生酮飲食具有高度可行性：在為期一個月的隨機對照試驗中，83%接受每日檢測的受試者維持生酮狀態；在延長至四個月的試驗中，這一比例達到94%；而且沒有人表示因採取生酮飲...